What Is Revumenib?

Revumenib is a prescription menin inhibitor used to treat certain types of acute leukemia in adults and children aged 1 year and older.

Sold under the brand name Revuforj, Revumenib is manufactured by Syndax Pharmaceuticals. It was first approved by the FDA in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation. In October 2025, the FDA expanded its approval to include relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation.

Revumenib belongs to a class of drugs called menin inhibitors, which are a newer type of targeted cancer therapy. It is not a controlled substance.

What Is Revumenib Used For?

Revumenib is approved for two specific uses:

1. Relapsed or refractory acute leukemia with a KMT2A translocation — in adult and pediatric patients aged 1 year and older.
2. Relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation — in patients who have no satisfactory alternative treatment options.

Both of these conditions involve specific genetic changes in leukemia cells. Your doctor must confirm these mutations through molecular testing before Revumenib can be prescribed. To learn more about how your doctor identifies these mutations, see our guide on finding a doctor who can prescribe Revumenib.

What Does "Relapsed or Refractory" Mean?

Relapsed means the leukemia came back after initial treatment. Refractory means the leukemia did not respond to previous treatment. Revumenib is designed for patients in these situations — it is not typically used as a first-line therapy.

How Is Revumenib Taken?

Revumenib comes as tablets in three strengths: 25 mg, 110 mg, and 160 mg.

Standard Dosing

• Adults and children weighing 40 kg or more: 270 mg taken by mouth twice daily
• With a strong CYP3A4 inhibitor: 160 mg twice daily (dose is reduced because these medications increase Revumenib levels in your body)
• Children weighing less than 40 kg: 160 mg/m² twice daily (or 95 mg/m² with a strong CYP3A4 inhibitor)

Important Instructions

• Take it fasting or with a low-fat meal (no more than 400 calories, with no more than 25% of those calories from fat).
• Swallow tablets whole. If you cannot swallow them, tablets can be crushed and mixed with water.
• Your white blood cell count must be below 25 Gi/L before starting treatment.
• Treatment should continue until disease progression or unacceptable side effects, with a minimum treatment duration of 6 months for patients without disease progression.

For a full breakdown of how Revumenib works in your body, read our guide on Revumenib's mechanism of action.

Who Should Not Take Revumenib?

While there are no absolute contraindications listed in the FDA labeling, Revumenib should not be started in patients with a QTcF interval greater than 450 milliseconds on their ECG. This is because of the drug's risk of QTc prolongation and potentially dangerous heart rhythms.

You should also not take Revumenib if:

• You are pregnant or planning to become pregnant — Revumenib can cause fetal harm.
• You are breastfeeding — nursing is not recommended during treatment or for 1 week after the last dose.
• You take strong or moderate CYP3A4 inducers — these medications can reduce Revumenib's effectiveness. See our drug interactions guide for details.

For a full list of side effects and warnings, see our guide on Revumenib side effects.

How Much Does Revumenib Cost?

Revumenib has a wholesale acquisition cost (WAC) of approximately $39,500 per month, or about $474,000 per year. There is currently no generic version available.

However, most patients pay significantly less than the list price:

• Revuforj Copay Program: Commercially insured patients may pay as little as $0 through the SyndAccess copay assistance program.
• Patient assistance: Uninsured or underinsured patients can apply for financial help through SyndAccess. Call 1-888-567-SYND (7963).
• Insurance coverage: Most commercial plans cover Revumenib with prior authorization, given its orphan drug designation and limited patient population.

For a complete guide to reducing your costs, read how to save money on Revumenib.

Final Thoughts

Revumenib represents a significant advancement in the treatment of specific types of acute leukemia. As the first commercially available menin inhibitor, it offers a targeted option for patients whose leukemia has relapsed or not responded to other treatments.

If you have been prescribed Revumenib and need help finding it, use Medfinder to check pharmacy availability near you. For questions about the medication, always consult your hematologist or oncologist.